NMRA earnings: real EPS beat/miss history, analyst consensus Buy, P/E -1.16. Updated 2026-07-23.
Neumora Therapeutics, Inc. Common Stock (NMRA) Research Hub
Neumora Therapeutics, Inc. Common Stock (NMRA) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 1.04 USD (-13.33%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -1.16, market cap 0.29B. This hub links to the full technical, earnings and options research available for NMRA.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 1.04 USD (-13.33%) |
| 52-week range | 0.83 USD – 1.85 USD |
| Trend regime | Range |
| 14-day RSI | 25.2 (Oversold) |
| Trailing P/E | -1.16 |
| Market cap | 0.29B |
| Dividend yield | 0.00% |
Available research for NMRA
Covered Call on NMRA: how it works, illustrative setup around the real 1.04 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on NMRA: how it works, illustrative setup around the real 1.04 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on NMRA: how it works, illustrative setup around the real 1.04 USD price, max profit/loss, breakeven and when to use it. Educational.
NMRA technical analysis: range, last 1.04 USD, RSI 25.2, 52w range 0.83 USD–1.85 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is NMRA in?
Neumora Therapeutics, Inc. Common Stock (NMRA) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is NMRA in an uptrend or downtrend?
As of 2026-09-11, NMRA is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is NMRA's trailing P/E ratio?
NMRA's trailing P/E is -1.16, with a market cap of 0.29B. See the earnings research page for full valuation detail.